Matheson R - Search Results

1

Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects.

Matheson R, Kempers S, Breneman D, Draelos Z, Johnson CE, Loss R, Hogan DJ, Schoenfeld R, Checketts S, Kircik L, Fivenson D, Hebert AA, Williams J, Hamlin R, Groisser D, Piacquadio D. Matheson R, et al. J Drugs Dermatol. 2008 Mar;7(3):266-71. J Drugs Dermatol. 2008. PMID: 18380208 Clinical Trial.

2

Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.

Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M; U0267-301 & 302 Study Investigators. Feldman SR, et al. Among authors: matheson r. Am J Clin Dermatol. 2012 Aug 1;13(4):261-71. doi: 10.2165/11630710-000000000-00000. Am J Clin Dermatol. 2012. PMID: 22587791 Clinical Trial.

3

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.

Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG. Gottlieb AB, et al. J Drugs Dermatol. 2013 Aug;12(8):888-97. J Drugs Dermatol. 2013. PMID: 23986162 Clinical Trial.

4

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis.

Krueger JG, Suárez-Fariñas M, Cueto I, Khacherian A, Matheson R, Parish LC, Leonardi C, Shortino D, Gupta A, Haddad J, Vlasuk GP, Jacobson EW. Krueger JG, et al. Among authors: matheson r. PLoS One. 2015 Nov 10;10(11):e0142081. doi: 10.1371/journal.pone.0142081. eCollection 2015. PLoS One. 2015. PMID: 26556603 Free PMC article. Clinical Trial.

5

Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes.

Rich P, Houpt KR, LaMarca A, Loven KH, Marbury TC, Matheson R, Miller B, Smith S, Wolf J; Tinea Corporis/Tinea Cruris Research Group. Rich P, et al. Among authors: matheson r. Cutis. 2001 Jul;68(1 Suppl):15-22. Cutis. 2001. PMID: 11499330 Clinical Trial.

6

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC. Reich K, et al. Among authors: matheson rt. Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8. Exp Dermatol. 2015. PMID: 25828362 Free PMC article. Clinical Trial.

7

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG. Sofen H, et al. J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025. J Allergy Clin Immunol. 2014. PMID: 24679469 Free article. Clinical Trial.

8

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.

Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, Lee JH. Korman N, et al. Among authors: matheson r. Arch Dermatol. 2005 Apr;141(4):467-73. doi: 10.1001/archderm.141.4.467. Arch Dermatol. 2005. PMID: 15837864 Clinical Trial.

9

Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.

Langley RG, Papp K, Bissonnette R, Toth D, Matheson R, Hultquist M, White B. Langley RG, et al. Among authors: matheson r. Int J Dermatol. 2010 Jul;49(7):818-28. doi: 10.1111/j.1365-4632.2010.04512.x. Int J Dermatol. 2010. PMID: 20618506 Clinical Trial.

10

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.

Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, McRae S, Fielder S, Lee JH. Jorizzo J, et al. Among authors: matheson r. J Am Acad Dermatol. 2007 Aug;57(2):265-8. doi: 10.1016/j.jaad.2007.01.047. Epub 2007 May 18. J Am Acad Dermatol. 2007. PMID: 17512087 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters